Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight‐loss outcomes. (18th July 2014)

• Record Type: Journal Article
• Authors: Smith, Steven R.; O'Neil, Patrick M.; Astrup, Arne; Finer, Nicholas; Sanchez‐Kam, Matilde; Fraher, Kyle; Fain, Randi; Shanahan, William R.
• Is Part Of: Obesity. Volume 22:Number 10(2014:Oct.)
• Page Start: 2137
• Page End: 2146
• Publication Date: 2014-07-18
• Subjects: Obesity -- Periodicals; 616.398005
• DOI: 10.1002/oby.20841
• Languages: English
• ISSNs: 1930-7381

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="oby20841-sec-0001" sec-type="section"> <title>Objective</title> <p>To identify an early treatment milestone that optimizes sensitivity and specificity for predicting ≥5% weight loss at Week (W) 52 in patients with and without type 2 diabetes on lorcaserin or placebo.</p> </sec> <sec id="oby20841-sec-0002" sec-type="section"> <title>Methods</title> <p>Post hoc area under the curve for receiver operating characteristic analyses of data from three phase 3 trials comparing lifestyle modification+placebo with lifestyle modification+lorcaserin. A total of 6897 patients (18–65 years; BMI, 30–45 or 27–29.9 kg/m<sup>2</sup> with ≥1 comorbidity) were randomized to placebo or lorcaserin 10 mg bid. Changes (baseline to W52) in cardiometabolic parameters were assessed.</p> </sec> <sec id="oby20841-sec-0003" sec-type="section"> <title>Results</title> <p>Response (≥5% weight loss from baseline) at W12 was a strong predictor of W52 response. Lorcaserin patients with a W12 response achieved mean W52 weight losses of 10.6 kg (without diabetes) and 9.3 kg (with diabetes). Proportions achieving ≥5% and ≥10% weight loss at W52 were 85.5% and 49.8% (without diabetes), and 70.5% and 35.9% (with diabetes). Lorcaserin patients who did not achieve a W12 response lost 3.2 kg (without diabetes) and 2.8 kg (with diabetes) at W52. Responders had greater improvements in cardiometabolic risk factors than the modified intent‐to‐treat (MITT) population, consistent with greater weight loss.</p> </sec> <sec id="oby20841-sec-0004" sec-type="section"> <title>Conclusions</title> <p>≥5% weight loss by W12 predicts robust response to lorcaserin at 1 year.</p> </sec> </abstract>